323 related articles for article (PubMed ID: 18795925)
1. Association of paediatric mastocytosis with a polymorphism resulting in an amino acid substitution (M541L) in the transmembrane domain of c-KIT.
Foster R; Byrnes E; Meldrum C; Griffith R; Ross G; Upjohn E; Braue A; Scott R; Varigos G; Ferrao P; Ashman LK
Br J Dermatol; 2008 Nov; 159(5):1160-9. PubMed ID: 18795925
[TBL] [Abstract][Full Text] [Related]
2. Mutations in the fifth immunoglobulin-like domain of kit are common and potentially sensitive to imatinib mesylate in feline mast cell tumours.
Isotani M; Yamada O; Lachowicz JL; Tamura K; Yagihara H; Fujino Y; Ono K; Washizu T; Bonkobara M
Br J Haematol; 2010 Jan; 148(1):144-53. PubMed ID: 19804453
[TBL] [Abstract][Full Text] [Related]
3. [Therapeutically relevant mutations in the receptor tyrosine kinase KIT in mastocytosis].
Sotlar K
Verh Dtsch Ges Pathol; 2007; 91():169-76. PubMed ID: 18314612
[TBL] [Abstract][Full Text] [Related]
4. Recent advances in the understanding of mastocytosis: the role of KIT mutations.
Orfao A; Garcia-Montero AC; Sanchez L; Escribano L;
Br J Haematol; 2007 Jul; 138(1):12-30. PubMed ID: 17555444
[TBL] [Abstract][Full Text] [Related]
5. Novel germline mutation of KIT associated with familial gastrointestinal stromal tumors and mastocytosis.
Hartmann K; Wardelmann E; Ma Y; Merkelbach-Bruse S; Preussner LM; Woolery C; Baldus SE; Heinicke T; Thiele J; Buettner R; Longley BJ
Gastroenterology; 2005 Sep; 129(3):1042-6. PubMed ID: 16143141
[TBL] [Abstract][Full Text] [Related]
6. Aberrant autophosphorylation of c-Kit receptor in canine mast cell tumor cell lines.
Takeuchi Y; Fujino Y; Watanabe M; Nakagawa T; Ohno K; Sasaki N; Sugano S; Tsujimoto H
Vet Immunol Immunopathol; 2010 Oct; 137(3-4):208-16. PubMed ID: 20591500
[TBL] [Abstract][Full Text] [Related]
7. Identification of a c-kit exon 8 internal tandem duplication in a feline mast cell tumor case and its favorable response to the tyrosine kinase inhibitor imatinib mesylate.
Isotani M; Tamura K; Yagihara H; Hikosaka M; Ono K; Washizu T; Bonkobara M
Vet Immunol Immunopathol; 2006 Nov; 114(1-2):168-72. PubMed ID: 16908071
[TBL] [Abstract][Full Text] [Related]
8. Identification of a polymorphism in the transmembrane domain of the protooncogene c-kit in healthy subjects.
Nagata H; Worobec AS; Metcalfe DD
Exp Clin Immunogenet; 1996; 13(3-4):210-4. PubMed ID: 9165275
[TBL] [Abstract][Full Text] [Related]
9. Analysis of c-kit gene integrity in aplastic anemia.
Paquette RL; Hsu NC; Koeffler HP
Blood Cells Mol Dis; 1996; 22(2):159-68. PubMed ID: 8931956
[TBL] [Abstract][Full Text] [Related]
10. KIT polymorphisms and mutations determine responses of neoplastic mast cells to bafetinib (INNO-406).
Peter B; Hadzijusufovic E; Blatt K; Gleixner KV; Pickl WF; Thaiwong T; Yuzbasiyan-Gurkan V; Willmann M; Valent P
Exp Hematol; 2010 Sep; 38(9):782-91. PubMed ID: 20685234
[TBL] [Abstract][Full Text] [Related]
11. A novel K509I mutation of KIT identified in familial mastocytosis-in vitro and in vivo responsiveness to imatinib therapy.
Zhang LY; Smith ML; Schultheis B; Fitzgibbon J; Lister TA; Melo JV; Cross NC; Cavenagh JD
Leuk Res; 2006 Apr; 30(4):373-8. PubMed ID: 16183119
[TBL] [Abstract][Full Text] [Related]
12. KIT and mastocytosis.
Lim KH; Pardanani A; Tefferi A
Acta Haematol; 2008; 119(4):194-8. PubMed ID: 18566536
[TBL] [Abstract][Full Text] [Related]
13. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm.
Longley BJ; Tyrrell L; Lu SZ; Ma YS; Langley K; Ding TG; Duffy T; Jacobs P; Tang LH; Modlin I
Nat Genet; 1996 Mar; 12(3):312-4. PubMed ID: 8589724
[TBL] [Abstract][Full Text] [Related]
14. Detection of mi transcription factor (MITF) mRNA in a case of myelodysplastic syndrome and bone marrow mastocytosis.
Wimazal F; Walchshofer S; Baghestanian M; Chott A; Sperr WR; Kopp C; Sillaber C; Semper H; Horny HP; Tröndle U; Födinger M; Schwarzinger I; Lechner K; Valent P
Wien Klin Wochenschr; 1998 Feb; 110(3):79-88. PubMed ID: 9553202
[TBL] [Abstract][Full Text] [Related]
15. Association of adult mastocytosis with M541L in the transmembrane domain of KIT.
Rocha J; Luz Duarte M; Marques H; Torres F; Tavares P; Silva A; Brito C
J Eur Acad Dermatol Venereol; 2010 Sep; 24(9):1118-9. PubMed ID: 20236206
[No Abstract] [Full Text] [Related]
16. Gain-of-function mutations in the extracellular domain of KIT are common in canine mast cell tumors.
Letard S; Yang Y; Hanssens K; Palmérini F; Leventhal PS; Guéry S; Moussy A; Kinet JP; Hermine O; Dubreuil P
Mol Cancer Res; 2008 Jul; 6(7):1137-45. PubMed ID: 18644978
[TBL] [Abstract][Full Text] [Related]
17. The prevalence of the c-kit exon 10 variant, M541L, in aggressive fibromatosis does not differ from the general population.
Grabellus F; Worm K; Sheu SY; Siffert W; Schmid KW; Bachmann HS
J Clin Pathol; 2011 Nov; 64(11):1021-4. PubMed ID: 21757432
[TBL] [Abstract][Full Text] [Related]
18. [Cutaneous mastocytosis].
Flageul B
Rev Prat; 2006 Oct; 56(16):1745-51. PubMed ID: 17315498
[TBL] [Abstract][Full Text] [Related]
19. Multiple novel alterations in Kit tyrosine kinase in patients with gastrointestinally pronounced systemic mast cell activation disorder.
Molderings GJ; Kolck UW; Scheurlen C; Brüss M; Homann J; Von Kügelgen I
Scand J Gastroenterol; 2007 Sep; 42(9):1045-53. PubMed ID: 17710669
[TBL] [Abstract][Full Text] [Related]
20. Clinical and molecular evidence for c-kit receptor as a therapeutic target in neuroblastic tumors.
Uccini S; Mannarino O; McDowell HP; Pauser U; Vitali R; Natali PG; Altavista P; Andreano T; Coco S; Boldrini R; Bosco S; Clerico A; Cozzi D; Donfrancesco A; Inserra A; Kokai G; Losty PD; Nicotra MR; Raschellà G; Tonini GP; Dominici C
Clin Cancer Res; 2005 Jan; 11(1):380-9. PubMed ID: 15671569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
